VK2735
InvestigationalA dual GLP-1/GIP receptor agonist from Viking Therapeutics with both subcutaneous and oral formulations. Phase 2 VENTURE trial showed 14.7% weight loss at 13 weeks (SC) and 12.2% (oral). Phase 3 VANQUISH-1 enrolled 4,500 patients.
Viking 2735
11 human studies
- Preclinical
- 8%
- Clinical
- 92%
Based on 12 cited sources
clinically demonstrated · moderate confidence
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 65: single adequately-powered Phase 2 RCT — VENTURE (PMID 41508550, NCT06068946, Obesity 2026), double-blind placebo-controlled dose-ranging, 140 active + 34 placebo over 13 weeks (1A=28 single RCT n>=50; 1B=14 one low-RoB Phase 2 trial, no systematic review; 1C=6 total human N~174 in the 50-300 band; 1D=13 direct population/SC route/weight outcome match; 1E=4 modest VK2735-specific preclinical base). Phase 3 VANQUISH-1 (4,650 enrolled) and the oral VENTURE arm are not yet PubMed-indexed so they do not raise the human-evidence tier. Mechanism 82: GLP-1R/GIPR are named targets with binding + functional agonist confirmation (2A=30), incretin target-to-effect pathway fully mapped (2B=26), monotonic dose-response in VENTURE 9.2 kg @2.5 mg to 14.6 kg @15 mg plus in-vivo (2C=17), confirmed in mammalian in-vivo (2D=9). Plausibility 90: full mechanism->surrogate->clinical chain since weight loss is itself the demonstrated human outcome (3A=34), fully coherent with incretin physiology (3B=24), strong same-class analogy from tirzepatide (3C=19), tightly scoped single-mechanism claim (3D=13). Global Coverage 33: single sponsor-led multicenter US trial, not yet independently replicated (4A=12), primarily one-country institutional breadth (4B=10), <5 VK2735-specific primary studies in the literature (4C=6), under active FDA-registered clinical trials but not approved anywhere (4D=5). Community Experience 31: niche enthusiast discussion only, investigational and not commercially available (5A=9), <3-year track record (5B=8), thin/mixed reports (5C=7), no notable recurring serious adverse community signal over limited exposure (5D=7). Effectiveness 79 (clinical, moderate confidence): ~13% placebo-subtracted weight loss at 13 weeks is large/transformative magnitude (E1=27), far exceeds the weight-management MCID with 93% achieving >=5% loss (E2=23), weight loss is a hard patient-relevant outcome (E3=13), superior to placebo on a clinical outcome but no head-to-head vs tirzepatide yet (E4=16); confidence moderate given a single short 13-week Phase 2 RCT with Phase 3 still unpublished.
The mechanisms of VK2735 are based on its dual GLP-1/GIP receptor agonism, a well-characterized pharmacological approach validated by tirzepatide approval.
How It Works (Simplified)
VK2735 activates two complementary hormone pathways for enhanced metabolic effects:
Binds GLP-1 receptors in brain and gut, reducing appetite, slowing gastric emptying, and enhancing glucose-dependent insulin release.
Activates GIP receptors on fat cells and pancreas, amplifying metabolic effects and potentially improving adipose tissue function.
Combined activation produces greater weight loss than either pathway alone, as demonstrated by tirzepatide vs semaglutide comparisons.
VK2735 oral formulation achieves systemic absorption without food restrictions, unlike oral semaglutide which requires fasting.
Key Research: VENTURE Phase 2 (2024) demonstrated 14.7% weight loss at 13 weeks with no plateau, suggesting continued efficacy with longer treatment.
Important Limitations
- Phase 3 data (VANQUISH-1) not yet available; efficacy based on Phase 2
- Long-term safety beyond 13 weeks not established in published data
- NOT commercially available - investigational drug only
- Comparison to approved agents (tirzepatide, semaglutide) requires Phase 3 results
Initial dose titration phase. GI side effects (nausea, diarrhea) most common during this period but typically mild-moderate. Early appetite suppression begins.
NCT06068946Continued weight loss with dose escalation. VENTURE data showed progressive weight reduction without plateau through week 13.
NCT06068946Phase 2 endpoint. 14.7% weight loss achieved at highest SC dose. Weight loss curves still declining, suggesting further reduction possible with longer treatment.
NCT06068946Phase 3 duration. VANQUISH-1 will evaluate 78-week efficacy and safety.
NCT07104500Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (4 indicators)
Warning Signs (3 indicators)
Bad Signs (3 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Tesamorelin
CompatibleDifferent mechanisms (GH-releasing vs incretin agonism). May have complementary effects on body composition. No interaction studies available.
BPC-157
CautionBoth affect GI function. VK2735 slows gastric emptying while BPC-157 is gastroprotective. Monitor GI symptoms if combined.
Tirzepatide
AvoidSame mechanism of action (dual GLP-1/GIP agonism). Concurrent use would be duplicative with increased risk of adverse effects. No clinical rationale for combination.
Semaglutide
AvoidOverlapping GLP-1 receptor agonism. Concurrent use would increase risk of GI adverse effects and hypoglycemia without additional benefit.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare VK2735
Related Peptides
5-Amino-1MQ
5-Amino-1-Methylquinolinium · NNMT Inhibitor
A small molecule NNMT inhibitor studied for metabolic effects in animal models. No human clinical trials have been conducted. Increases NAD+ levels in adipose tissue in preclinical studies.
Amycretin
NNC0487-0111 · Oral Amycretin · Subcutaneous Amycretin
A novel single-molecule dual GLP-1/amylin receptor agonist developed by Novo Nordisk. Unlike CagriSema (a fixed-dose combination), amycretin is a unified peptide that activates both pathways. Phase 1 trials showed superior weight loss signals versus semaglutide, with both oral and subcutaneous formulations in development.
AOD-9604
Anti-Obesity Drug 9604 · Tyr-hGH Fragment 177-191 · hGH Fragment 176-191
A modified fragment of human growth hormone (amino acids 176-191 with N-terminal tyrosine) studied for fat loss. Clinical development discontinued after Phase 2b/3 trials failed to show efficacy in 536 subjects. Now prohibited by WADA and excluded from FDA compounding.
Cagrilintide
AM833 · NN9838
A long-acting amylin analog developed by Novo Nordisk for weight management. Studied in Phase 3 trials as CagriSema (combination with semaglutide). The Phase 3 REDEFINE 1 trial showed -20.4% weight loss with cagrilintide-semaglutide versus -3.0% with placebo at 68 weeks.
CagriSema
Cagrilintide-Semaglutide · NNC0174-0833
A fixed-dose combination of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist) for chronic weight management. Phase 3 REDEFINE trials demonstrate 20-23% weight loss at 68 weeks. NDA submitted to FDA December 2025. First GLP-1/amylin combination therapy.
CT-388
RG-6912
A dual GLP-1/GIP receptor agonist (INN enicepatide; also RO7795068) acquired by Roche through the $2.7 billion Carmot Therapeutics acquisition in 2024. The published Phase 1 trial (NCT04838405) showed 4.7-8.0% mean weight loss vs 0.5% placebo over 4 weeks; a more widely reported ~18.8% placebo-adjusted figure at 24 weeks comes from an unpublished Phase 1 extension reported via press release. Phase 2 obesity and T2D trials are completed or ongoing and Phase 3 began in 2026, positioning it as a competitive obesity therapeutic with a mechanism similar to tirzepatide.